Adalimumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Adalimumab and local guidelines before prescribing.
Mechanism
Monoclonal antibody that binds and neutralises TNF-alpha.
Uses
Rheumatoid, psoriatic and juvenile arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, psoriasis, uveitis.
Dosing
- Infliximab (IV 5 mg/kg at weeks 0, 2 and 6, then every 8 weeks; subcutaneous versions are available) and adalimumab (subcutaneous).
Gastroenterology: Inflammatory Bowel Disease
Side effects
Infections, injection-site reactions, headache; reactivated TB, demyelination, lupus-like syndrome, heart failure worsening.
Interactions
Avoid with other biologics; live vaccines contraindicated; methotrexate reduces antibody formation.
Contraindications and cautions
Active infection, moderate to severe heart failure, demyelinating disease
Monitoring
TB and hepatitis B screen; FBC; signs of infection
Pregnancy and breastfeeding
Limited data; specialist advice
Renal and hepatic impairment
No dose adjustment
Overdose and reversal
No antidote; stop if infection
Special advice
Screen for TB and hepatitis B; check varicella status; stop and seek advice during serious infection; avoid in moderate to severe heart failure.
More from the textbook: uses, cautions and other points
- Infliximab (IV), adalimumab (SC), golimumab (UC) | TNF-alpha | Moderate to severe Crohn's and UC, perianal fistulas; TB reactivation , serious infections, worsens heart failure, demyelination, drug-induced lupus, paradoxical psoriasis, lymphoma (especially with thiopurines); infusion reactions; antibody formation - check drug …
Gastroenterology: Anatomy Physiology Pharmacology - Biosimilars - cheaper versions of infliximab and adalimumab; switching is usually safe.
Gastroenterology: Anatomy Physiology Pharmacology - Adalimumab Subcutaneous | Anti-TNF; self-injected.
Gastroenterology: Inflammatory Bowel Disease - Crohn's - exclusive enteral nutrition (liquid formula only for 6–8 weeks) is first-line induction (as effective as steroids, better for growth); steroids if not suitable; maintenance with azathioprine or methotrexate; anti-TNF (infliximab, adalimumab) for moderate to severe disease; surgery for complications.
Paediatrics: Gastroenterology and surgery in children - Infliximab / adalimumab | Moderate to severe IBD; TB screening first.
Paediatrics: Gastroenterology and surgery in children - Biologics - etanercept, adalimumab (also for uveitis), tocilizumab and anakinra (systemic JIA).
Paediatrics: Neurology, bones and joints in children
Where it is discussed in the book
- Gastroenterology: Anatomy Physiology Pharmacology (3 mentions)
- Gastroenterology: Inflammatory Bowel Disease (2 mentions)
- Paediatrics: Gastroenterology and surgery in children (2 mentions)
- Paediatrics: Neurology, bones and joints in children (2 mentions)
- Dermatology: Skin basics, eczema and psoriasis (2 mentions)
- Dermatology: Urticaria, drug reactions, blistering, ulcers and emergencies (2 mentions)
- Rheumatology Anatomy Physiology Pharmacology (1 mention)
- Rheumatology: assessment, investigations and drugs (3 mentions)
- Rheumatology: Inflammatory arthritis (4 mentions)
- Rheumatology: Vasculitis, GCA and PMR (2 mentions)
- Ophthalmology: Anatomy Physiology and Pharmacology (1 mention)
- ID: Hospital infection, the immunocompromised host, vaccination and public health (2 mentions)
- Clinical Immunology: Immune system basics and immunological investigations (2 mentions)
- Clinical Immunology: Secondary immunodeficiency, the immunocompromised host and vaccination (6 mentions)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (8 mentions)
- Integrated paediatrics chapter (4 mentions)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (2 mentions)